Drug
High Dose Anavex2 73
High Dose Anavex2 73: highest development phase Phase 2/3, developed by Anavex Life Sciences. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- Anavex Life Sciences
Trials
| Drug | Phase | Indication |
|---|---|---|
| High dose ANAVEX2-73 NCT03790709 | Phase 2/3 | Alzheimer Disease |
| High dose ANAVEX2-73 NCT03774459 | Phase 2 | Parkinsons Disease With Dementia |
Latest
No recent events.
Follow High Dose Anavex2 73 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.